NS
Natarajan Sethuraman
President, Research & Develop.

Natarajan Sethuraman insider trades: Entrada Therapeutics (TRDA) stock sales

President, Research & Develop., Entrada Therapeutics Last trade May 4, 2026 22 Form 4 filings
$399K
Sold, last 12 months
1 sale
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2023
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Natarajan reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 4, 2026TRDA↓ Sell$399K
Dec 3, 2024TRDA↓ Sell$321K
Nov 13, 2024TRDA↓ Sell$82K
Nov 6, 2024TRDA↓ Sell$339K
Oct 16, 2024TRDA↓ Sell$11K
Sep 9, 2024TRDA↓ Sell$49K
Jul 15, 2024TRDA↓ Sell$22K
May 20, 2024TRDA↓ Sell$288K
Jul 11, 2023TRDA↓ Sell$322K
Apr 17, 2023TRDA↓ Sell$71K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other TRDA insiders

Open-market trades in the last 12 months

About Natarajan Sethuraman's insider trades

Natarajan Sethuraman is President, Research & Develop. at Entrada Therapeutics (TRDA). Since Apr 17, 2023, Natarajan has reported no open-market purchases and 10 sales worth $1.9M on SEC Form 4. In the last 12 months: 1 sale ($399K).

Their filings also include grants and awards (9 filings), shares withheld for taxes (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRDA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.